Clinical Rheumatology

, Volume 11, Issue 4, pp 483–485 | Cite as

Systemic sclerosis in the elderly

  • L. Czirják
  • Z. Nagy
  • G. Szegedi
Originals
First Online:
Received:
Revised:
Accepted:

Summary

In our study, the characteristics of 114 patients with systemic sclerosis (SSc) are discussed with emphasis on the subgroup of cases whose onset of disease occurred above the age of 60 years. Seven out of the 9 cases showed symptoms of diffuse cutaneous systemic sclerosis with an extensive skin involvement, and 5 of these cases died within 2 years following the onset of SSc. Seven of the 9 cases showed a rapid disease course with symptoms of cardiac, pulmonary and/or renal involvement, while no secondary Sjögren's syndrome, subcutaneous calcinosis and myositis were demonstrated among these patients.

Key words

Scleroderma Systemic Sclerosis Old Onset Clinical Study 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Czirják, L., Schlammadinger, J., Szegedi, G. Anticentromere antibody and Raynaud phenomenon. Dermatologica 1991, 183, 55.CrossRefPubMedGoogle Scholar
  2. 2.
    Czirják, L., Bokk, Á., Csontos, G., Lörincz, G., Szegedi, G. Clinical findings in patients with progressive systemic sclerosis. Acta Derm Venereol (Stockh.) 1989, 69, 533–36.Google Scholar
  3. 3.
    Lally, E.V., Jimenez, S.A., Kaplan, S.R. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum 1988, 18, 1–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Subcommittee for scleroderma. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23, 581–590.CrossRefGoogle Scholar
  5. 5.
    LeRoy, C.E., Krieg, T., Black, C., Medsger, T.A.Jr., Fleischmajer, R., Rowell, N., Jablonska, S., Wollheim, F. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis (editorial). J Rheumatol 1988, 15, 202–205.PubMedGoogle Scholar
  6. 6.
    Tamási, L., Dézsi, Á., Sonkoly, I., Kiss, E., Balázs, C., Szegedi, G. Examination of the epidemiology of immunopathological diseases in inhabitats of Hajdu-Bihar county (abstract in English). Orvosi Hetilap 1987, 128, 2101–2105.PubMedGoogle Scholar
  7. 7.
    Medsger, T.A., Masi, A.T., Rodnan, G.P., Benedek, T.G., Robinson. Survival with systemic sclerosis (scleroderma): A lifetable analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971, 75, 369–37.CrossRefPubMedGoogle Scholar
  8. 8.
    Wynn, J., Fineberg, N., Matzer, L., Cortada, X., Armstrong, W., Dillon, C., Kinney, E. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985, 110, 123–12.CrossRefPubMedGoogle Scholar
  9. 9.
    Barnett, A.J. Scleroderma (Progressive systemic sclerosis): Progress and course based on a personal series of 118 cases Med J Aust 1978, 2, 129–134.PubMedGoogle Scholar
  10. 10.
    Bennett, R., Bluestone, R., Holt, P.J.L., Bywaters, E.G.L. Survival in scleroderma. Ann Rheum Dis 1971, 30, 581–588.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Medsger, T.A., Masi, A.T. Survival with scleroderma. II: A lifetable analysis of clinical and demographic factors in 358 male US veteran patients. J Chron Dis 1973, 26, 647–660.CrossRefPubMedGoogle Scholar
  12. 12.
    Norton, W.L., Nardo, J.M. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 1970, 73, 317–324.CrossRefPubMedGoogle Scholar
  13. 13.
    Rodnan, G.P. Progressive systemic sclerosis: Clinical features and pathogenesis of cutaneous involvement scleroderma. Clin Rheum Dis 1979, 5, 49–7.Google Scholar
  14. 14.
    Medsger, T.A. Jr., Masi, A.T. Epidemiology of systemic sclerosis (scleroderma) among US male veterans J Chron Dis 1978, 31, 73–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Leinwand, I., Duryee, A.S., Richter, M.N. Scleroderma (based on a study of over 150 cases). Ann Intern Med 1954, 41, 1003–1041.CrossRefPubMedGoogle Scholar
  16. 16.
    Farmer, R.G., Gifford, R.W., Hines E.A. Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma: A study of 271 cases. Circulation 1960, 21, 1088–1095.CrossRefPubMedGoogle Scholar
  17. 17.
    Peters-Golden, M., Wise, R.A., Hochberg, M.C., Stevens, M.B., Wigley, F. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 1984, 77, 1027–1034.CrossRefPubMedGoogle Scholar
  18. 18.
    Catoggio, L.J., Bernstein, R.M., Black, C.M., Hughes, G.R.V., Maddison, P.J., Serological markers in progressive systemic sclerosis. Clinical correlations. Ann Rheum Dis 1983, 42, 23–27.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Tuffanelli, D.L., Winkelmann, R.K. Systemic scleroderma: A clinical study of 727 cases. Arch Dermatol 1961, 84, 359–371.CrossRefPubMedGoogle Scholar

Copyright information

© Acta Medica Belgica 1992

Authors and Affiliations

  • L. Czirják
    • 1
  • Z. Nagy
    • 1
  • G. Szegedi
    • 1
  1. 1.3rd Department of MedicineUniversity Medical School of DebrecenHungary

Personalised recommendations